Skip to main content
OpenTrials
Completed

NCT Number: NCT05644639

Study of StimRouter for Chronic Knee OA Pain

The goal of this study is to evaluate the use of StimRouter Neuromodulation System (StimRouter) in adult subjects with an established diagnosis of primary femorotibial osteoarthritis in the target knee (Kellgren-Lawrence ≥1) who have surgical contraindications to undergo a knee joint arthroplasty procedure. The main questions it aims to answer are:

1. To assess the effect of the StimRouter Neuromodulation System to manage joint pain in patients with symptomatic OA of the knee who are surgically contraindicated to undergo a knee joint arthroplasty 2. To assess the effect of StimRouter on joint stiffness, function and patient quality of life

Participants will have StimRouter leads implanted then clinic visits will be scheduled for follow-up at Week 2, Month 3 and Month 6 (End of Study (EOS) or Early Termination (ET)).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Osteoarthritis Rheumatic Diseases

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mendelson Kornblum Orthopedic and Spine Specialists

Livonia, Michigan, 48154, United States

About this study

This study will be a single-center, single-arm, open label pilot study evaluating the safety and efficacy of the StimRouter Neuromodulation System as a peripheral nerve stimulator targeting knee joint innervation of moderately to severely symptomatic subjects with OA of the knee who are non-eligible to undergo a joint arthroplasty at the target knee.

Up to 30 subjects will be enrolled and participate in the study. Clinic visits will be scheduled at Screening, Stimulation Trial Procedure, Trial Assessment Visit, Implant Procedure and Follow-up Week 2, Month 3 and Month 6 (End of Study (EOS) or Early Termination (ET)).

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is at least 21 years of age at the time of giving informed consent
  • Radiographic disease Stage ≥ 1 in the target knee according to the Kellgren-Lawrence grading of knee OA
  • Knee joint arthroplasty procedure is contraindicated
  • Full understanding of the requirements of the study and willingness to comply with all study visits and assessments
  • Subjects must have read and understood the informed consent form, and must have signed it prior to any study-related procedure being performed

Exclusion criteria

  • Subject has undergone previous joint arthroplasty procedure (partial, total, patella-femoral) to the index knee
  • Unresolved effusion of the target knee clinically requiring aspiration within 12 weeks prior to Visit 1 (Baseline)
  • Treatment of the index knee with systemic or intra-articular corticosteroids (e.g., methylprednisolone) within 6 weeks prior to Visit 1 (Baseline)
  • Visco-supplementation (e.g., hyaluronic acid) in the index knee within 6 weeks prior to Visit 1 (Baseline)
  • Subject has an active systemic infection or an active local infection in or near the index knee joint, or has a previous history of joint infection.
  • Subject with bleeding disorders or active anticoagulation that cannot be stopped for a few days prior to the time of the surgical procedure.
  • Subject who has an active or existing skin disorder or irritation, which, in the opinion of the Investigator, precludes the use of skin gel electrodes.
  • Subjects has or plans to have a pacemaker, defibrillator, cochlear implant, and/or a sleep apnea implant.
  • Subject has or plans to have a Spinal Cord Stimulator (SCS), Peripheral Nerve field Stimulation system (PNfS), Dorsal Root Ganglion system (DRG), or implantable infusion pump.
  • Subject who currently requires or is likely to require Magnetic Resonance Imaging (MRI) within the MRI exclusion zone: the entire PNS lead must be at least 50 cm from the center of the MRI system's bore (the iso-center) and at least 16 cm outside of the MRI coil measured from the edge of the MRI coil.
  • Female subject who is pregnant or nursing or plans to become pregnant during the study. The effects of electrical stimulation on pregnancy are not known. Do not use electrical stimulation (including StimRouter) during pregnancy.
  • Any condition and findings in the medical history or in the pre-study assessments, that in the opinion of the Investigator, constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation
  • Comorbid conditions that could affect pain assessment of the target knee, including, but not limited to, inflammatory rheumatic conditions such as rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus

Treatment and study plan

StimRouter Neuromodulation System

Device

The StimRouter device is indicated for pain management in adults who have severe, intractable chronic pain of peripheral nerve origin and as an adjunct to other modes of therapy (e.g., medications). The StimRouter device is not intended to treat pain of craniofacial nerve origin.

Other names: StimRouter

Primary outcomes

  1. Knee Pain

    Time frame: The primary endpoint is at Month 3 post permanent implantation.

    Change in pain with a Numeric Rating Scale (minimum 0 and maximum 10) from Baseline to 3 months after treatment

  2. Knee Pain

    Time frame: The primary endpoint is at Month 3 post permanent implantation.

    Change in pain from Baseline to Month 3 in knee health as assessed by the KOOS-12 questionnaire. The KOOS-12 questionnaire is a 12-item measure derived from the original 42 item Knee injury and Ostoearthritis Outcome Score (KOOS). KOOS-12 contains 4 KOOS Pain items, 4 KOOS Function (Activities of Daily Living and Sport/Recreation) items, and 4 KOOS Quality of Life (QOL) items.

Secondary outcomes

  1. Serious Adverse Events (SAEs)

    Time frame: The primary endpoint is at Month 3 post permanent implantation.

    Frequency and proportion of device, or procedure-related Serious Adverse Events (SAEs) in subjects who receive permanent implant of the StimRouter Neuromodulation System

  2. Serious Adverse Events (SAEs)

    Time frame: Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.

    Frequency and proportion of device, or procedure-related Serious Adverse Events (SAEs) in subjects who receive permanent implant of the StimRouter Neuromodulation System

  3. Adverse Events (AEs)

    Time frame: The primary endpoint is at Month 3 post permanent implantation.

    Frequency and proportion of device, or procedure-related non-serious adverse events (AEs) in subjects who receive permanent implant of the StimRouter Neuromodulation System

  4. Adverse Events (AEs)

    Time frame: Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.

    Frequency and proportion of device, or procedure-related non-serious adverse events (AEs) in subjects who receive permanent implant of the StimRouter Neuromodulation System

  5. Secondary Interventions

    Time frame: The primary endpoint is at Month 3 post permanent implantation.

    Rate of secondary interventions (e.g. surgical or intra-articular injection) to the index knee

  6. Secondary Interventions

    Time frame: Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.

    Rate of secondary interventions (e.g. surgical or intra-articular injection) to the index knee

  7. Knee Pain

    Time frame: Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.

    Change in pain with a Numeric Rating Scale (minimum 0 and maximum 10) from Baseline to 6 months after treatment

  8. Knee Health

    Time frame: Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.

    Change in pain from Baseline to Month 6 in knee health as assessed by the KOOS-12 questionnaire. The KOOS-12 questionnaire is a 12-item measure derived from the original 42 item Knee injury and Ostoearthritis Outcome Score (KOOS). KOOS-12 contains 4 KOOS Pain items, 4 KOOS Function (Activities of Daily Living and Sport/Recreation) items, and 4 KOOS Quality of Life (QOL) items.

  9. Pain Experience

    Time frame: The primary endpoint is at Month 3 post permanent implantation.

    the change from baseline to Month 3 in pain experience (pain catastrophizing) as assessed by the PCS questionnaire scale score.

  10. Pain Experience

    Time frame: Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.

    the change from baseline to Month 6 in pain experience (pain catastrophizing) as assessed by the PCS questionnaire scale score

  11. Treatment Satisfaction Scores

    Time frame: Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.

    Treatment Satisfaction is measured using a 5 question questionnaire with answers ranging from "Very Satisfied" to "Very Dissatisfied"

  12. Forgotten Joint Score (FJS)

    Time frame: The primary endpoint is at Month 3 post permanent implantation.

    The FJS-12 Questionnaire comprises measures for assessment of joint-specific patient reported outcomes that focuses on subject's awareness of affected joint in everyday life. Joint awareness defined as any unintended perception of a joint. Subjects rate awareness of their knee joint in 12 questions with a 5-point Likert response format: "Never", "almost never", "seldom", "sometimes" and "mostly". Scores are summed & linearly transformed in a 0-100 scale with a high value reflecting subject's ability to forget the affected knee joint during daily living activities.

  13. Forgotten Joint Score (FJS)

    Time frame: Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.

    The FJS-12 Questionnaire comprises measures for assessment of joint-specific patient reported outcomes that focuses on subject's awareness of affected joint in everyday life. Joint awareness defined as any unintended perception of a joint. Subjects rate awareness of their knee joint in 12 questions with a 5-point Likert response format: "Never", "almost never", "seldom", "sometimes" and "mostly". Scores are summed & linearly transformed in a 0-100 scale with a high value reflecting subject's ability to forget the affected knee joint during daily living activities.

  14. Health-Related Quality of Life (HRQOL)

    Time frame: The primary endpoint is at Month 3 post permanent implantation.

    the change from baseline to Month 3 in Health-Related Quality of Life (HRQOL) as assessed by the PROMIS-10 Global Health questionnaire. The PROMIS-10 is a 10 question questionnaire with answers ranging from "Excellent" to "Poor"

  15. Health-Related Quality of Life (HRQOL)

    Time frame: Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.

    the change from baseline to Month 6 in Health-Related Quality of Life (HRQOL) as assessed by the PROMIS-10 Global Health questionnaire. The PROMIS-10 is a 10 question questionnaire with answers ranging from "Excellent" to "Poor"

  16. Treatment Satisfaction Scores

    Time frame: The primary endpoint is at Month 3 post permanent implantation.

    Treatment Satisfaction is measured using a 5 question questionnaire with answers ranging from "Very Satisfied" to "Very Dissatisfied"

  17. Treatment Expectation Scores

    Time frame: The primary endpoint is at Month 3 post permanent implantation.

    Treatment Expectation is measured using a 3 question questionnaire with subjects assessing their expectations of treatment ranging from "Too Low - I'm a lot better than I thought" to "Too High - I'm somewhat worse than I thought"

  18. Treatment Expectation Scores

    Time frame: Patients will continue to be followed up to Month 6 to gather additional efficacy and safety data.

    Treatment Expectation is measured using a 3 question questionnaire with subjects assessing their expectations of treatment ranging from "Too Low - I'm a lot better than I thought" to "Too High - I'm somewhat worse than I thought"

Sponsors and collaborators

Lead sponsor

Bioventus LLC

Industry

Registry information

Official study title

StimRouter Genicular NeuromoduLation for Chronic KnEe OsteoArthritic Pain Management

Acronym: GLEAM

Important dates

Study start
2022
Primary completion
2023
Study completion
2024
First posted
Dec 9, 2022
Registry last updated
Jun 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.